[ad_1]
It may take some time before that Amazon formalize and complete the acquisitions of One Medical (1Life Healthcare) and iRobot, both announced this summer for $ 3.9 and $ 1.7 billion respectively. The possible delay is to be attributed to American FTCdetermined to investigate both issues with the underlying concern that the e-commerce giant will hire one dominant position on the market and gain an advantage over competitors through the collection of user data (an example: Amazon could obtain valuable information from the analysis of the maps of the house generated by the robot to offer the consumer furniture products).
It is legitimate that the US commission wants to see clearly, since these are transactions that, once concluded, will lead the company founded by Jeff Bezos to have a a strong role both in healthcare and in the connected devices sector. What worries the new CEO Andy Jassy – at the head of the company for a year – is mainly the figure of Lina KhanPresident of the FTC since June 2021 and known for his hard punch against the big names of the web. Amazon’s Antitrust Paradox is the title of his treaty published in 2017 in which he accuses the Seattle company (and not only) of violating the laws on free market competition.
Analyzes on One Medical and iRobot started last week, and both run the risk of lengthening the deadline for closing operations. Not only: the risk that everything will end in nothingness is not such a remote hypothesis. Just think, for example, of the role that the FTC played in Nvidia’s renunciation of acquiring Arm: at the end of last year, in fact, it had completed the investigation by stating that the $ 40 billion operation violated competition rules.
[ad_2]
Source link
